Known targets — ChEMBL curated mechanism
HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7
The experimentally established mechanism targets of Dexfenfluramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.64 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.57 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.43 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.43 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.43 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenfluramine SCHEMBL16215 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL15669714 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL29447403 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL29499611 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL162006 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL29882976 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL23724055 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL11140094 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL39491 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL30951308 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16056 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107229-A1 | REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025136206-A1 | A NASAL DEVICE FOR USE IN DRUG DELIVERY VIA THE NASAL CAVITY | NOSEOPTION AB (SE) | 2025-06-26 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250122274-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | SCHOLAR ROCK, INC. | 2025-04-17 | — | — | US | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | claimed |
| EP-0301925-B1 | PROCESS FOR THE ENANTIOSPECIFIC PREPARATION OF (S)2-ETHYL AMINO-1-3-(TRIFLUOROMETHYL PHENYL) PROPANE | ADIR ET COMPAGNIE (FR) | 1991-10-23 | — | — | EP | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| US-4999382-A | Compositions for treating tobacco withdrawal symptoms and methods for their use | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-03-12 | — | — | US | claimed |
| US-4971998-A | MENSTRUATION, FENFLURAMINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-11-20 | — | — | US | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| US-4857553-A | SIDE EFFECT REDUCTION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-15 | — | — | US | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | claimed |
| EP-0253146-A2 | The use of D-Fenfluramine for the manufacture of medicaments for treating depression | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1988-01-20 | — | — | EP | claimed |